Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

US Healthcare Ishares ETF (NY: IYH )

58.06 -0.07 (-0.12%)
Official Closing Price Updated: 8:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 311,271
Open 58.48
Bid (Size) 56.67 (26)
Ask (Size) 59.13 (25)
Prev. Close 58.13
Today's Range 57.98 - 58.55
52wk Range 57.98 - 310.69
Shares Outstanding 556,000
Dividend Yield 8.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Target, Apollo Global Management, Las Vegas Sands And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors named Apollo Global Management, Inc. 
Via Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga

Performance

YTD
-80.03%
-80.03%
1 Month
-4.65%
-4.65%
3 Month
-80.11%
-80.11%
6 Month
-78.62%
-78.62%
1 Year
-79.37%
-79.37%

More News

Read More
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Via Benzinga
Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy
Via Benzinga
Humana, Comerica, Cleveland-Cliffs, And More: CNBC's 'Final Trades'
Via Benzinga
Cisco, Burlington Stores, Broadcom And More On CNBC's 'Final Trades'
Via Benzinga
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
Via Benzinga
Exposures Product Safety
All eyes on the Fed as inflation metrics give mixed signals
Via Talk Markets
Topics Economy
Exposures Interest Rates
Beyond The Hustle: Embracing Ancient Chinese Wisdom To Combat Modern Day Burnout
Via Benzinga
4 Top-Ranked Sector ETFs To Buy In The Second Half
Via Talk Markets
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Via Benzinga
The 3 Most Promising Industries to Invest in for 2023’s Second Half
Via InvestorPlace
Stocks Flounder Despite Inflation Downtrend As Banking Crisis Emerges, But Outlook Remains Encouraging
Via Talk Markets
Got $10,000? Buy These 2 Market-Beating ETFs for the Long Haul
Via The Motley Fool
Uncertainties On Fed Policy, Geopolitics, And Earnings Cloud 2023 Outlook, But Trends Are Promising
Via Talk Markets
Worried About 2023? Here's a Safer Way to Invest in Stocks This Year
Via The Motley Fool
The 3 Best Sectors to Invest in for 2023
Via InvestorPlace
Health Care Exposure Ahead Of CPI Data, Progressive, Dollar General And Seagate Technology Feature On CNBC's 'Final Trades'
Via Benzinga
Investors Await Bullish Catalysts As Inflation, Interest Rates, And Money Supply Growth Show Signs Of Topping
Via Talk Markets
CNBC's Final Trades: Microsoft, US Dollar Index, iShares Healthcare ETF And This Cybersecurity Tech Major
Via Benzinga
Adobe Earnings Strangle Trade
Via Talk Markets
Why WHO Did Not Recommend Convalescent Plasma Therapy For COVID-19
Via Benzinga
Exposures COVID-19
New Drug Applications Pile Up With FDA As Pandemic Still Sore Spot For Delayed Inspections
Via Benzinga
Exposures Product Safety
Entering Q4 with mix of optimism and caution suggests hedged long positioning
Via Talk Markets
4 Defensive Sector ETFs to Protect Your Portfolio
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.